Lipoprotein Electrophoresis Test

The Lipoprotein Electrophoresis test is a specialised blood investigation that separates serum lipoproteins into distinct fractions according to their electrical mobility. It may be used when a routine lipid profile shows unusual or complex abnormalities and the doctor requires additional information about the pattern of cholesterol- and triglyceride-carrying particles.

Lipids such as cholesterol and triglycerides do not dissolve freely in blood. They are transported inside particles called lipoproteins, which contain varying proportions of lipid and specialised proteins known as apolipoproteins. The major circulating groups include chylomicrons, very-low-density lipoproteins, intermediate-density lipoproteins, low-density lipoproteins, and high-density lipoproteins.

During electrophoresis, serum is applied to a supporting medium, commonly agarose gel, and exposed to an electric field. Lipoproteins move at different rates according to their charge, size, and composition. The resulting bands are analysed visually or quantitatively to identify the distribution of major fractions.

The electrophoretic fractions are traditionally described as chylomicrons, beta lipoproteins, pre-beta lipoproteins, and alpha lipoproteins. These broadly correspond to different lipoprotein groups, although electrophoretic classification is not identical to modern particle measurement. Beta lipoproteins are mainly associated with LDL, pre-beta lipoproteins with VLDL, and alpha lipoproteins with HDL.

Lipoprotein electrophoresis may also be used for lipoprotein phenotyping or the traditional Fredrickson classification of hyperlipoproteinemia. It is particularly useful in selected patients with suspected type III hyperlipoproteinemia, also called familial dysbetalipoproteinemia or broad-beta disease.

The test is not a replacement for a routine lipid profile, apolipoprotein B, lipoprotein(a), non-HDL cholesterol, genetic testing, or cardiovascular risk assessment. Results must be interpreted with fasting status, total cholesterol, triglycerides, LDL cholesterol, HDL cholesterol, family history, clinical findings, medicines, and secondary causes of dyslipidemia.

Lipoprotein Fractions Evaluated

Chylomicrons: Chylomicrons are large, triglyceride-rich particles formed in the intestine after fat-containing meals. They transport dietary triglycerides and cholesterol. Chylomicrons are usually absent or minimal after an adequate fast. Persistent fasting chylomicrons may be seen in severe chylomicronemia and selected primary or secondary lipid disorders.

Beta Lipoproteins: The beta band is composed mainly of LDL particles. LDL transports cholesterol from the liver to peripheral tissues. Increased LDL-related beta activity may be associated with an elevated risk of atherosclerotic cardiovascular disease, although treatment decisions generally use standard LDL cholesterol, non-HDL cholesterol, apolipoprotein B, and the patient's overall risk.

Pre-Beta Lipoproteins: The pre-beta fraction is associated mainly with VLDL particles, which transport triglycerides produced by the liver. Increased pre-beta activity may accompany hypertriglyceridemia, diabetes, obesity, alcohol use, hypothyroidism, kidney disease, certain medicines, or inherited lipid disorders.

Alpha Lipoproteins: The alpha fraction is associated mainly with HDL. HDL participates in reverse cholesterol transport and other metabolic functions. A reduced alpha fraction may accompany low HDL cholesterol, but electrophoresis is not the primary method for assessing HDL-related cardiovascular risk.

Broad-Beta Pattern: A broad beta band spanning the usual beta and pre-beta regions may indicate the accumulation of cholesterol-rich remnant particles seen in familial dysbetalipoproteinemia. Confirmation requires correlation with lipid ratios, apolipoprotein measurements, APOE genotype or phenotype, clinical findings, and secondary factors.

Benefits of Lipoprotein Electrophoresis

• Separates serum lipoproteins into major electrophoretic fractions.
• Provides a visual or quantitative pattern of abnormal lipoprotein distribution.
• May help classify complex hyperlipoproteinemia patterns.
• Supports investigation of suspected familial dysbetalipoproteinemia.
• Can identify fasting chylomicron persistence.
• May distinguish predominant LDL-related from VLDL-related abnormalities.
• Complements total cholesterol, triglycerides, HDL cholesterol, and LDL cholesterol.
• May support specialist assessment of severe or unusual dyslipidemia.
• Can contribute to the traditional Fredrickson lipoprotein phenotype classification.
• Provides additional information when routine lipid results do not fully explain the clinical pattern.

Clinical Indications and Applications

Unusual Lipid-Profile Results: Testing may be considered when cholesterol and triglycerides are both substantially abnormal, the pattern is inconsistent, or routine calculated LDL cholesterol is unreliable because of high triglycerides.

Suspected Familial Dysbetalipoproteinemia: This disorder involves accumulation of remnant lipoproteins and may produce elevations in both cholesterol and triglycerides. Electrophoresis may show a characteristic broad-beta pattern.

Familial dysbetalipoproteinemia is often associated with particular APOE variants, but genotype alone may not establish the clinical phenotype. Diabetes, hypothyroidism, obesity, menopause, alcohol use, kidney disease, and other factors can contribute to its expression.

Severe Hypertriglyceridemia: Lipoprotein electrophoresis may help determine whether fasting chylomicrons, VLDL, or both are increased. Very high triglycerides can increase the risk of acute pancreatitis and require prompt medical management.

Suspected Inherited Dyslipidemia: Patients with premature cardiovascular disease, very high cholesterol or triglycerides, recurrent pancreatitis, xanthomas, or a strong family history may require specialist lipid assessment. Electrophoresis may be one component of this evaluation.

Secondary Dyslipidemia: Abnormal patterns may result from uncontrolled diabetes, hypothyroidism, obesity, kidney disease, liver disease, excess alcohol intake, pregnancy, or medicines. These causes must be investigated before classifying a pattern as a primary inherited condition.

Fredrickson Phenotyping: The traditional classification groups hyperlipoproteinemia according to the predominant particle pattern. Although useful descriptively, it does not identify every underlying genetic cause and does not replace modern cardiovascular risk assessment.

Why Doctors Recommend This Test

Doctors recommend lipoprotein electrophoresis when standard lipid measurements do not provide enough information about an unusual dyslipidemia. The test can show whether chylomicrons, beta, pre-beta, or alpha fractions predominate and whether a broad-beta pattern is present.

A routine lipid profile remains the first-line assessment for most patients. Electrophoresis is generally reserved for selected complex cases and is commonly interpreted by a cardiologist, endocrinologist, lipid specialist, or physician.

The result may guide further testing, including direct LDL cholesterol, non-HDL cholesterol, apolipoprotein B, apolipoprotein A-I, lipoprotein(a), APOE testing, genetic lipid panels, thyroid function, glucose or HbA1c, kidney function, and liver tests.

The test does not directly determine whether cholesterol deposits are present in arteries. Cardiovascular risk assessment also considers age, blood pressure, diabetes, smoking, family history, kidney disease, and previous cardiovascular events.

Preparation Before the Test

A 12 to 15-hour fast is generally required. During the fasting period, consume only plain water unless the doctor provides different instructions. Do not consume tea, coffee, milk, juice, food, chewing gum, or caloric drinks.

The patient should ideally follow a stable diet and maintain stable body weight for at least one to two weeks before collection. Sudden dieting, fasting beyond the instructed period, binge eating, or major changes in fat and carbohydrate intake can alter the pattern.

Avoid alcohol for at least 24 hours before collection or according to laboratory instructions. Alcohol can increase triglycerides and affect VLDL and chylomicron patterns.

Inform the doctor about all prescription medicines, non-prescription medicines, lipid-lowering treatment, hormones, steroids, retinoids, diuretics, antipsychotics, supplements, and herbal products. Do not stop treatment unless instructed by the prescriber.

Tell the doctor about diabetes, thyroid disease, kidney disease, liver disease, pregnancy, recent acute illness, infection, surgery, weight change, or a recent heart attack. Acute illness can temporarily change lipid measurements.

Provide a family history of premature heart disease, stroke, severe hypertriglyceridemia, pancreatitis, xanthomas, and known inherited lipid disorders.

What Happens During the Test?

A trained phlebotomist confirms fasting status and collects a blood sample from a vein, usually in the arm. The sample is placed in a suitable serum tube and processed to separate serum.

The procedure usually takes only a few minutes. Mild discomfort, bruising, tenderness, or minor bleeding may occur. Serious complications are uncommon.

The serum is applied to an electrophoretic medium and exposed to an electric field. The separated lipoprotein bands are stained and analysed. The laboratory may also report total cholesterol, triglycerides, serum appearance, relative fraction intensity, and an interpretive phenotype.

Specimen handling is important because lipoprotein particles may be affected by improper storage. The serum is transported at the temperature specified by the performing laboratory.

Normal Reporting Time

The report for the Lipoprotein Electrophoresis test is generally available within 4 to 8 working days. It is a specialised investigation that may be performed in scheduled batches or at a referral laboratory.

Reporting may take longer if the sample requires repeat separation, additional staining, specialist interpretation, or confirmation. Patients should confirm the expected turnaround time with Focus Diagnostics.

Who Should Consider This Test?

• Patients with unusual or complex lipid-profile abnormalities.
• Individuals with suspected familial dysbetalipoproteinemia.
• Patients with severe fasting hypertriglyceridemia.
• Individuals with persistent fasting chylomicrons.
• Patients with recurrent pancreatitis and a suspected lipid cause.
• People with premature cardiovascular disease and possible inherited dyslipidemia.
• Individuals with xanthomas or other physical signs of abnormal lipid accumulation.
• Patients with a strong family history of severe cholesterol or triglyceride disorders.
• Individuals referred by a lipid specialist, cardiologist, endocrinologist, or physician.
• Patients whose routine lipid profile requires further phenotypic clarification.

Understanding the Test Results

The report may describe chylomicrons and the beta, pre-beta, and alpha fractions, along with total cholesterol, triglycerides, serum appearance, and an interpretation. Results depend on fasting status and the laboratory method.

Increased Chylomicrons: Persistent fasting chylomicrons may occur in severe chylomicronemia. Causes include inherited defects in triglyceride clearance and secondary factors such as uncontrolled diabetes, alcohol use, obesity, kidney disease, and certain medicines.

Increased Beta Fraction: A prominent beta band generally reflects increased LDL-related lipoproteins. Standard LDL cholesterol, non-HDL cholesterol, apolipoprotein B, and cardiovascular risk assessment are required for management.

Increased Pre-Beta Fraction: A prominent pre-beta fraction generally reflects increased VLDL and may accompany elevated triglycerides. The doctor investigates metabolic, dietary, medication-related, and inherited causes.

Broad-Beta Pattern: A broad band extending through the beta and pre-beta regions may support familial dysbetalipoproteinemia. Confirmation may involve apolipoprotein measurements, remnant-related calculations, APOE testing, and evaluation of secondary factors.

Reduced Alpha Fraction: A reduced alpha fraction may correlate with low HDL, but the significance must be assessed using direct HDL cholesterol and overall cardiovascular risk.

The electrophoretic phenotype can change with treatment, diet, diabetes control, thyroid function, alcohol consumption, and body weight. It does not necessarily identify one specific genetic cause.

Clinical Limitations

Lipoprotein electrophoresis is not a first-line cardiovascular screening test. It does not replace a standard lipid profile or validated risk assessment.

Failure to fast adequately can cause chylomicrons to appear and may produce an inaccurate phenotype. Recent dietary changes, alcohol, acute illness, pregnancy, and medicines can also alter the pattern.

The test does not directly measure LDL particle number, apolipoprotein B, lipoprotein(a), or every remnant particle. Separate assays are needed.

The Fredrickson phenotype describes the lipoprotein pattern but does not define the exact genetic mutation or distinguish every primary and secondary cause.

Important Safety Information

Very high triglycerides can cause acute pancreatitis. Seek urgent medical care for severe upper-abdominal pain, persistent vomiting, fever, or pain radiating to the back.

Do not stop lipid-lowering treatment or make extreme dietary changes based only on an electrophoresis report. Treatment should be guided by a qualified healthcare professional.

This information is intended for general education and does not replace diagnosis or advice from a lipid specialist, cardiologist, endocrinologist, or physician. Always discuss the result with the referring doctor.